KR940001902A - 쓴 약제의 맛-차단 조성물 - Google Patents

쓴 약제의 맛-차단 조성물 Download PDF

Info

Publication number
KR940001902A
KR940001902A KR1019930014564A KR930014564A KR940001902A KR 940001902 A KR940001902 A KR 940001902A KR 1019930014564 A KR1019930014564 A KR 1019930014564A KR 930014564 A KR930014564 A KR 930014564A KR 940001902 A KR940001902 A KR 940001902A
Authority
KR
South Korea
Prior art keywords
composition
bitter
alkaline earth
bacterial infection
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019930014564A
Other languages
English (en)
Other versions
KR100242399B1 (ko
Inventor
에스.카타니아 조셉
디. 존슨 알톤
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR940001902A publication Critical patent/KR940001902A/ko
Application granted granted Critical
Publication of KR100242399B1 publication Critical patent/KR100242399B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

본 발명은 쓴 약제, 맛-차단 성분 및 약제적으로 허용 가능한 담체로 이루어진, 쓴맛이 감소된 약학 조성물에 관한 것이다.
상기 쓴맛-차단성분은 알칼리 토 산화물, 알칼리 토수산화물 또는 알칼리 수산화물이며, 이는 약제의 활성을 방해하지 않는다.

Description

쓴 약제의 맛-차단 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 쓴 약제 ; 알칼리 토 산화물 및 알칼리 토 수산화물로 이루어 진 그룹 중에서 선택된 염기성 화합물 ; 및 약학적으로 허용가능한 담체를 포함하는, 쓴맛이 감소된 약학 조성물.
  2. 제1항에 있어서, 상기 염기성 화합물이 알칼리 토 산화물인 조성물
  3. 제2항에 있어서, 상기 쓴 약제가 아자라이드인 조성물.
  4. 제3항에 있어서, 상기 알칼리 토 산화물이 산화 마그네슘인 조성물.
  5. 제4항에 있어서, 상기 아자라이드가 아지쓰로마이신인 조성물.
  6. 제1항에 있어서, 알돈산 또는 그의 약학적으로 허용가능한 염을 추가로 포항하는 조성물.
  7. 제6항에 있어서, 상기 알돈산이 약학적으로 허용가능한 염으로서 존재하는 조성물.
  8. 제7항에 있어서, 상기 알돈산화염이 글루콘산 칼슘인 조성물.
  9. 제8항에 있어서, 상기 염기성 화합물이 알칼리 토 산화물인 조성물.
  10. 제9항에 있언서, 상기 쓴 약제가 아자라이드인 조성물.
  11. 제10항에 있어서, 상기 알칼리 토 산화물이 산화 마그네슘인 조성물.
  12. 제11항에 있어서, 상기 아자라이드가 아지쓰로마이신인 조성물.
  13. 쓴 약제를 제1항에 따른 약락 조성물로서 배합함을 포함하는, 상기 쓴 약제의 쓴맛을 감소시키는 방법.
  14. 세균감염으로 고통받는 포유동물에게 항균 유효량의 제3항에 따른 약학 조성물을 투여함을 포항하는, 상기 포유동물의 세균 감염 치료방법.
  15. 세균감염으로 고통받는 포유동물에게 항균 유효량의 제10항에 따른 약학 조성물을 투여함을 포함하는, 상기 포유동물의 세균 감염 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930014564A 1992-07-30 1993-07-29 쓴 약제의 맛-차단 조성물 Expired - Fee Related KR100242399B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92226292A 1992-07-30 1992-07-30
JP922,262 1992-07-30
US922,262 1992-07-30
JP93-083225 1993-04-09

Publications (2)

Publication Number Publication Date
KR940001902A true KR940001902A (ko) 1994-02-16
KR100242399B1 KR100242399B1 (ko) 2000-03-02

Family

ID=25446788

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930014564A Expired - Fee Related KR100242399B1 (ko) 1992-07-30 1993-07-29 쓴 약제의 맛-차단 조성물

Country Status (29)

Country Link
US (1) US5633006A (ko)
EP (1) EP0582396B1 (ko)
JP (1) JP2685403B2 (ko)
KR (1) KR100242399B1 (ko)
CN (1) CN1030964C (ko)
AT (1) ATE198421T1 (ko)
AU (1) AU655892B2 (ko)
CA (1) CA2101466C (ko)
CZ (1) CZ285057B6 (ko)
DE (1) DE69329810T2 (ko)
DK (1) DK0582396T3 (ko)
EG (1) EG20385A (ko)
ES (1) ES2153836T3 (ko)
FI (1) FI933404L (ko)
GR (1) GR3035426T3 (ko)
HR (1) HRP931049B1 (ko)
HU (1) HU221682B1 (ko)
IL (1) IL106451A (ko)
MX (1) MX9304577A (ko)
MY (1) MY110581A (ko)
NO (1) NO308023B1 (ko)
NZ (1) NZ248280A (ko)
PL (1) PL174795B1 (ko)
PT (1) PT582396E (ko)
RU (1) RU2126257C1 (ko)
SK (1) SK280194B6 (ko)
TW (1) TW271400B (ko)
YU (1) YU52593A (ko)
ZA (1) ZA935475B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100259607B1 (ko) * 1995-08-08 2000-06-15 가시오 가즈오 추가 표시영역을 가지는 전기적으로 제어된 복굴절 액정표시장치 및 그것을 구동시키는 방법
KR100809911B1 (ko) * 1999-02-18 2008-03-06 후소카가쿠코교 가부시키가이샤 마스킹제

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
GB9725219D0 (en) * 1997-11-29 1998-01-28 Cleansharp Ltd Tablets
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
AU2002327418A1 (en) * 2001-08-01 2003-02-17 Bristol-Myers Squibb Company Taste masking composition
KR20040032942A (ko) * 2001-08-21 2004-04-17 화이자 프로덕츠 인코포레이티드 호흡기 감염증을 치료하기 위한 일회분량의 아지트로마이신
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
NZ532707A (en) * 2001-12-21 2006-07-28 Pfizer Prod Inc Directly compressible formulations of azithromycin
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
MXPA04007427A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formulaciones de azitromicina granuladas por via seca.
RU2203670C1 (ru) * 2002-02-19 2003-05-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Лекарственный препарат антибактериального действия и способ его получения
EP2450044A1 (en) * 2002-04-26 2012-05-09 Fancl Corporation Difructose anhydride-containing composition for use in inhibiting dental caries
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
HRP20050867A2 (en) * 2003-04-02 2005-12-31 Pliva - Istra�ivanje i razvoj d.o.o. Pharmaceutical compositions having reduced bitter taste
KR100503949B1 (ko) * 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
US20070185194A1 (en) * 2003-07-01 2007-08-09 Kamal Mehta Stable oral compositions of azithromycin monohydrate
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (en) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
AP2218A (en) * 2003-12-04 2011-04-20 Pfizer Prod Inc Azithromycin dosage forms with reduced side effects
RU2331410C2 (ru) 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053651A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
JP2007513147A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060024335A1 (en) * 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
JP2006052169A (ja) * 2004-08-12 2006-02-23 Wakoudou Kk ゾル状又はゲル状の服薬補助食品
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2016202290B2 (en) * 2005-06-17 2017-10-05 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
JP4963846B2 (ja) * 2006-03-03 2012-06-27 エルメッド エーザイ株式会社 口腔内崩壊錠及びその製造方法
MX2008011823A (es) * 2006-03-16 2008-10-31 Novartis Ag Forma de dosificacion solida que contiene un agente activo de sabor encubierto.
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
EP2030644A1 (en) * 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
TWI592159B (zh) 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
WO2009099830A2 (en) * 2008-01-31 2009-08-13 Mcneil-Ppc, Inc. Edible film-strips for immediate release of active ingredients
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
JP5259880B2 (ja) * 2010-09-01 2013-08-07 興和株式会社 経口剤
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
WO2013129889A2 (ko) * 2012-02-28 2013-09-06 주식회사 서울제약 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN103961368B (zh) * 2013-12-05 2017-01-04 广西大学 蒙脱石负载的氢氧化钙抗酸剂
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) * 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN122182527A (zh) 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
BR112021009468A2 (pt) * 2018-11-16 2021-08-10 Ssp Co., Ltd. formulação farmacêutica oral contendo ibuprofeno
TW202110437A (zh) * 2019-05-23 2021-03-16 美商希諾瓦有限責任公司 用於酒精誘發之皮膚潮紅之治療及緩解的組成物及方法
MX2023007464A (es) * 2020-12-22 2023-08-30 Solugen Inc Agente de enmascaramiento amargo.
WO2022229494A1 (en) * 2021-04-28 2022-11-03 Mika Tapio Reijonen A composition of the energy drink and a method of its manufacturing
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
WO2026161854A1 (en) 2025-01-27 2026-07-30 eSpraye, Inc. Chemotherapeutic microparticle compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627885A (en) * 1968-07-18 1971-12-14 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding
US4127645A (en) * 1976-05-21 1978-11-28 Life Savers, Inc. Effervescent tablet and method
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
US4761274A (en) * 1986-03-27 1988-08-02 Warner-Lambert Company Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
JP2831004B2 (ja) * 1988-09-29 1998-12-02 大日本製薬株式会社 粉粒状医薬製剤
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH05139996A (ja) * 1991-11-15 1993-06-08 Lion Corp 苦味が軽減された鎮咳去痰製剤用組成物
IL104093A (en) * 1991-12-31 1999-06-20 Abbott Lab Prolamine is expected to mask the taste of drugs given orally
JPH05255120A (ja) * 1992-03-12 1993-10-05 Taisho Pharmaceut Co Ltd 苦み隠蔽製剤
DE4216756C2 (de) * 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
GB9211148D0 (en) * 1992-05-26 1992-07-08 Smithkline Beecham Plc Novel treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100259607B1 (ko) * 1995-08-08 2000-06-15 가시오 가즈오 추가 표시영역을 가지는 전기적으로 제어된 복굴절 액정표시장치 및 그것을 구동시키는 방법
KR100809911B1 (ko) * 1999-02-18 2008-03-06 후소카가쿠코교 가부시키가이샤 마스킹제

Also Published As

Publication number Publication date
CN1030964C (zh) 1996-02-14
JP2685403B2 (ja) 1997-12-03
FI933404A7 (fi) 1994-01-31
NO308023B1 (no) 2000-07-10
GR3035426T3 (en) 2001-05-31
DE69329810D1 (de) 2001-02-08
DK0582396T3 (da) 2001-04-09
SK280194B6 (sk) 1999-09-10
HU221682B1 (hu) 2002-12-28
AU4426193A (en) 1994-04-28
IL106451A0 (en) 1993-11-15
CZ285057B6 (cs) 1999-05-12
SK82193A3 (en) 1994-02-02
IL106451A (en) 1998-04-05
HUT64692A (en) 1994-02-28
PT582396E (pt) 2001-04-30
FI933404A0 (fi) 1993-07-29
CA2101466A1 (en) 1994-01-31
MX9304577A (es) 1994-02-28
NZ248280A (en) 1995-07-26
ATE198421T1 (de) 2001-01-15
JPH06206824A (ja) 1994-07-26
CA2101466C (en) 2000-06-06
FI933404L (fi) 1994-01-31
CN1083728A (zh) 1994-03-16
CZ151893A3 (en) 1994-03-16
ES2153836T3 (es) 2001-03-16
HRP931049B1 (en) 2001-06-30
EP0582396A1 (en) 1994-02-09
RU2126257C1 (ru) 1999-02-20
DE69329810T2 (de) 2001-06-21
PL299865A1 (en) 1994-02-07
EP0582396B1 (en) 2001-01-03
US5633006A (en) 1997-05-27
ZA935475B (en) 1995-01-29
TW271400B (ko) 1996-03-01
NO932736D0 (no) 1993-07-29
MY110581A (en) 1998-08-29
NO932736L (no) 1994-01-31
HRP931049A2 (en) 1997-08-31
KR100242399B1 (ko) 2000-03-02
PL174795B1 (pl) 1998-09-30
HU9302213D0 (en) 1993-10-28
YU52593A (sh) 1996-05-20
AU655892B2 (en) 1995-01-12
EG20385A (en) 1999-02-28

Similar Documents

Publication Publication Date Title
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
EP1658858A3 (en) Use of botulinum toxin for the treatment of unstable bladder
CA2263972A1 (en) 6-o-substituted ketolides having antibacterial activity
IL109448A0 (en) Risperidone pamoate, its preparation and pharmaceutical compositions containing it
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
CA2316919A1 (en) Novel macrolides
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
GB0031312D0 (en) Macrolides
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
NO20001439L (no) 3'-N-modifiserte 6-O-substituerte erytromycin ketolid- derivater med antibakteriell aktivitet
CA2547990A1 (en) Pharmaceutical compositions and methods for insulin treatment
PT876388E (pt) Derivados de eritromicina triciclica
ATE161265T1 (de) Derivate von 16-gliedrigen antibiotischen macroliden
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
MXPA04000324A (es) Una combinacion farmaceutica sinergistica para la prevencion o tratamiento de diabetes.
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
KR920701229A (ko) 에리트로마이신 유도체
WO2003089446A3 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
BR9807444A (pt) Produto antimicrobial
DE3260277D1 (en) Peptide antibiotic, component b, process for its preparation and its use in medicines
KR890015747A (ko) 클라마이디아 트라코마티스 감염증의 단일용량 근육내 투여 치료 방법
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
DE3260276D1 (en) Peptide antibiotic, component a, process for its preparation and its use in medicines

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

St.27 status event code: A-3-3-V10-V12-crt-PJ2001

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

St.27 status event code: A-3-3-V10-V12-crt-PJ2001

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19980805

Effective date: 19990520

PJ1302 Judgment (patent court)

St.27 status event code: A-3-3-V10-V15-crt-PJ1302

Decision date: 19990520

Decision identifier: 1998201007202

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 1997 1397 (1993 14564)

Appeal request date: 19980805

Appellate body name: Patent Court

J221 Remand (intellectual property tribunal)

Free format text: REMAND (INTELLECTUAL PROPERTY TRIBUNAL) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2201 Remand (intellectual property tribunal)

St.27 status event code: A-3-3-V10-V14-crt-PJ2201

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 1998 7202 (1993 14564)

Appellate body name: Patent Examination Board

Appeal request date: 19990624

Decision identifier: 1999131000023

Decision authority category: Office appeal board

Decision date: 19990710

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19990624

Effective date: 19990710

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 19990710

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 1998 7202 (1993 14564)

Appeal request date: 19990624

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 1999131000023

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20071005

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20081111

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20081111

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000